Pulmonx Corporation Competitors, Revenue and Alternatives

Claim your profile


Total Funding:$122M
Industry:Medical Equip
Lead Investor(s):Oxford Finance LLC
Claim your profile

Industry Ranking

Growjo 10k Ranking

Estimated Revenue & Financials

  • Pulmonx Corporation's estimated annual revenue is currently $43.2M per year.
  • Pulmonx Corporation received $20.0M in venture funding in September 2014.
  • Pulmonx Corporation's estimated revenue per employee is $251,000
  • Pulmonx Corporation's total funding is $122M.

Employee Data

  • Pulmonx Corporation has 172 Employees.
  • Pulmonx Corporation grew their employee count by 29% last year.
  • Pulmonx Corporation currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Caldera Medical
JenaValve Techn...
Neural Analytic...
Semler Scientif...
Bigfoot Biomedi...
Trice Imaging
OASIS Medical
Missing a competitor? Contribute!?

Pulmonx is focused on developing life-changing technologies that improve the lives of patients suffering from lung disease. The Company's first commercial products address emphysema, a form of COPD (chronic obstructive pulmonary disease) and the largest unmet medical need in Pulmonology. With emphysema, breathing becomes increasingly more difficult as the disease progresses. Today in the U.S., advanced emphysema patients have no available alternatives but lung volume reduction surgery, which is associated with high morbidity and mortality, and lung transplantation, which is limited by the availability of donor organs. Pulmonx has developed the Zephyr Endobronchial Valve (EBV) Therapy, a non-surgical, investigational approach to treating emphysema. The minimally invasive Zephyr valve is a tiny, one-way valve designed to reduce the volume of the diseased regions of the lung by blocking airflow, in order to improve breathing and increase activity levels. No surgery is involved in the simple, one-hour procedure. More than 25,000 Zephyr valves have been implanted outside the U.S. in the last 10 years. Clinical studies in Europe have shown that the majority of qualified patients who have the procedure see a significant improvement in lung function, exercise tolerance and quality of life. In the United States, Pulmonx is conducting the LIBERATE Clinical Study to evaluate the safety and effectiveness of the Zephyr valve in patients with severe emphysema. Pulmonx products are commercially available in Europe, Australia, Asia, Latin America and other countries worldwide. The company does not yet market or sell its products in the United States. CAUTION: The Zephyr Endobronchial Valve is an investigational device in the US, limited by US law to investigational use.



Number of Employees


Revenue (est)


Current Jobs


Employee Growth %


Total Funding







Executive Contacts

Charlie WagnerTerritory ManagerEmail Available
Heather FernleyTerritory ManagerEmail Available
Jared KatcherTerritory ManagerEmail Available
Narinder Singh ShargillVice President, Global Medical And Clinical AffairsEmail Available
Carla MartinsClinical Research ManagerEmail Available
Jim OutlawRegional Business DirectorEmail Available
Beran RoseVice President, Marketing And Business DevelopmentEmail Available
Michele NavarroSenior Manager, Marketing CommunicationsEmail Available
Ross EisonTerritory ManagerEmail Available
Kyle MillerRegional Business Director- West RegionEmail Available

Pulmonx Corporation News

08/28/2019 - Pulmonx Announces that Priority Health Now Covers the ...

BUSINESS WIRE)--Pulmonx Corporation, a leader in therapeutic pulmonary device technologies, announced today that its Zephyr® Valve is ...

09/03/2019 - Endobronchial Valve Market

Pulmonx Corporation (Zephyr) and Spiration Inc are investing in the development and introduction of new endobronchial valve products. The Zephyr Valve ...

05/09/2019 - Pulmonx Closes $65 Million Financing and Adds Chief ...

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation, a global leader in diagnostic and therapeutic pulmonary device ...

Pulmonx Corporation Funding

DateAmountRoundLead InvestorsReference
2007-05-08$20.4MB-1De Novo Ventures, Latterell Venture PartnersArticle
2010-01-20$11.5MUndisclosedDe Novo Ventures, Latterell Venture PartnersArticle
2014-09-18$20.0MUndisclosedOxford Finance LLCArticle

Pulmonx Corporation Acquisitions

DateCompany NameAmountNotesReference
2015-01-09Aeris Therapeutics IncArticle